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Abstract: We previously found that downregulation of protein kinase Cα (PKCα) can inhibit 
retinal pigment epithelium (RPE) cell proliferation involved in the development of proliferative 
vitreoretinopathy (PVR). In this study, we tested whether PKCα could be downregulated via 
small interfering RNA (siRNA)-PKCα released from foldable capsular vitreous body (FCVB) 
in cultured human RPE cells. SiRNA-PKCα content, determined by ultraviolet (UV) spec-
trophotometer, was released from FCVB containing 200, 300, 400, 500, and 600 nm siRNA-
PKCα in a time-dependent manner from 1 to 96 hours and a dose-dependent manner at five 
concentrations. The content (y) had a good linear relationship with time (x), especially in the 
600 nm siRNA-PKCα group (y = 16.214x, R2 = 0.9809). After treatment with siRNA-PKCα 
released from FCVBs, the PKCα was significantly decreased by RT-PCR, Western blot, and 
immunofluorescence analysis in RPE cells. These results indicate that PKCα was significantly 
downregulated by siRNA-PKCα released from FCVB in human RPE cells and provide us with 
a new avenue to prevent PVR.
Keywords: small interfering RNA–protein kinase Cα, foldable capsular vitreous body, drug 
delivery system, retinal pigment epithelium, protein kinase Cα
Introduction
Proliferative vitreoretinopathy (PVR) is a severe complication of retinal detachment 
and the most common reason for the failure of retinal detachment surgery.1,2 The risk 
of PVR varies from 10% to 40% depending on the original diseases.3,4 The pathology 
of PVR involves a complex network of relationships of cellular and humoral factors, in 
which proliferating retinal pigment epithelium (RPE) cells are thought to be an initiating 
factor.5–8 Protein kinase C (PKC) is an intracellular enzyme family, which transduces 
extracellular signals into intracellular responses. It has been well documented that the 
PKC family is involved in a series of life phenomena such as cell communication, 
secretion, ion channel regulation, cell proliferation and differentiation, and cancer, 
implying it is an ideal target for blocking signal transduction.9–12 Our previous study 
found that, of the ten kinds of PKC isoforms expressed in RPE cells, only PKCα is 
downstream of the confluence of the complex PVR network, which can promote RPE 
cell proliferation by downregulation of p27 Kip1.13,14 All of these studies strongly suggest 
that PKCα is an ideal and special blocking target for PVR.
Drug delivery to the posterior segments of the eye presents considerable challenges, 
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are usually ineffective due to the existence of critical barriers 
(such as corneal, blood–retinal, and blood–aqueous barriers) 
and short drug half-lives.15,16 Considering these challenges, 
development of a drug delivery system (DDS) is becoming 
increasingly important in the treatment of vitreoretinal dis-
eases not only to facilitate drug efficacy but also to attenuate 
adverse effects.17
In our previous studies, we discovered that foldable cap-
sular vitreous body (FCVB) is a public release vehicle DDS 
and can sustainably and mechanically release dexamethasone 
sodium phosphate (DexP) via the capsule apertures.18 In the 
clinical trial (ClinicalTrials.gov number, NCT00910702) 
evaluating the flexibility, efficacy, and safety of an FCVB 
in the treatment of severe retinal detachment, the FCVB 
was shown to be flexible, effective, and safe as a vitreous 
substitute over a 3-month implantation time. The FCVB 
used in the clinical trial consists of a thin vitreous-shaped 
capsule with a tube-valve system made using computer and 
industrial technology.19–21
RNA interference (RNAi) is an ancient and common 
biological phenomenon discovered in vivo in recent years.22 
It is commonly used as a powerful tool in biological and 
biomedical research and has been used experimentally to 
prevent ocular neovascularization and inflammation.23–25 
In our previous research, small interfering RNA (siRNA)-
PKCα), a specific inhibitor of PKCα, was shown to be able 
to inhibit RPE cell proliferation.14 Therefore, in this study, 
we investigate whether PKCα could be downregulated via 
siRNA-PKCα released from FCVB in cultured human RPE 
cells, providing us with a new avenue to prevent PVR.
Materials and methods
Characteristics of sirNA-PKCα
SiRNA-PKCα was purchased from Ribuo Biotech   (Guangzhou, 
China). The sequence of siRNA-PKCα was: positive-sense 
strand 5′GGCGUCCUGUUGUAUGAAAdAdT3′, antisense 
strand 3′dTdACCGCAGGACAACAUACUUU5′. Chemi-
cally synthesized siRNA-PKCα was mixed the suspension 
of two deoxyribose nucleotides to increase the stability in its 
3′ end. Lyophilized powder of siRNA-PKCα was dissolved in 
TE buffer (110 mM Tris⋅HCl, 1 mM EDTA, pH = 8.00) into 
the stock concentration of 20 µM, and stored at −20°C.
Basic material and fabrication  
of the FCVB
FCVB is made of tailor-made modified liquid silicone rubber, 
which consists of a vitreous-like capsule and a tube-valve 
system (shown in Figure 1A). The basic material, Dow 
siRNA-PKCα + FCVB
B
A Capsule
Tube
Valve
Figure 1 small interfering rNA–protein kinase Cα (sirNA-PKCα) sustained-release studies in vitro. (A) Foldable capsular vitreous body (FCVB) consists of a thin (60 µm) 
vitreous-like capsule mimicked by computer with a tube-valve system. (B) sirNA-PKCα at concentrations of 200, 300, 400, 500, and 600 nM in Te buffer was injected into 
the capsules of FCVB, which were immersed in cups of modified Frans diffusion cells. Two hundred (200) µL liquid was aspirated at time intervals of 1, 2, 3, 6, 9, 12, 24, 48, 
72, and 96 hours.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Corning Class VI elastomer, was purchased from Dow 
Corning Company (Midland, MI). The details of FCVB were 
described in our previous study.19
In vitro drug sustained-release studies
In a typical experiment, siRNA-PKCα at concentrations of 
200, 300, 400, 500, and 600 nm in TE buffer was injected 
into the capsules of the FCVBs, and the FCVBs were sepa-
rately immersed in five cups of modified Franz diffusion 
cells (shown in Figure 1B) and 4 mL of TE buffer as release 
medium was transferred into each cup. These cups were 
kept in an orbital shaker maintained at 37°C with constant 
agitation. Two hundred microliters (200 µL) of the release 
medium was aspirated for measurement at 1, 2, 3, 6, 9, 12, 
24, 48, 72, and 96 hours, and then the same amount of fresh 
medium was added into the cups. The collected samples were 
stored in a refrigerator. The siRNA-PKCα content in the 
liquid was then detected by UV spectrophotometer (DU800; 
Beckman Coulter, Brea, CA).
sirNA-PKCα sample assay in vitro
First, a standard curve was made to demonstrate the effective-
ness of the assay method. In brief, the 20 µM siRNA-PKCα 
stock solution was serially diluted with TE buffer to the 
desired concentrations: 20, 40, 60, 80, 100, 200, 300, 400, 
500, and 600 nm. Samples of 100 µL were transferred into 
the cuvette chamber. Samples were assayed at the absor-
bance of 260 nm, and 100 µL of TE buffer was added to 
blank the background. Calibrations were made using Excel 
software (2003; Microsoft, Redmond, WA).
Micromorphology of the FCVB
The capsule of the FCVB was cut into a 1-cm diameter disc, 
and then the sample was cleaned, coated with gold, and fixed 
on a specimen stub. The image of the specimen surface was 
captured with a scanning electron microscope (XL 30 ESEM 
FEG; FEI-Philips, Eindhoven, the Netherlands). Examina-
tions were carried out at 10 kV and in a humid atmosphere 
of approximately 1.8–2.0 Torr. Individual parameters are 
visible in the scale bar of each image.
human rPe cell culture
Human RPE cells were isolated within 24 hours of death 
from donor eyes, which were obtained from the Eye 
Bank of the Zhongshan Ophthalmic Center as previously 
described.26 The project was approved by the Ethics Com-
mittee of the Zhongshan Ophthalmic Center and followed 
the tenets of the Declaration of Helsinki. RPE cells were 
cultured in   Dulbecco’s modified Eagle’s medium (DMEM; 
Invitrogen-Gibco, Karlsruhe, Germany) containing 10% 
fetal bovine serum, penicillin G (100 µg/mL), streptomycin 
sulfate (100 mg/mL), and L-glutamate in Corning culture 
plates. The cells were maintained at 37°C in 5% CO2 in a 
humidified atmosphere, and those between the third and 
sixth passages were used for all experiments.
Treatment of human rPe cells with 
sirNA-PKCα released from FCVB
Human RPE cells grown in transwells (Corning Inc, 
  Corning, NY) were incubated for 12 hours. The culture 
media was then replaced with DMEM without serum or 
antibiotics, and filter inserts (8 µm pore size) carrying 
FCVBs containing 400, 500, and 600 nm siRNA-PKCα 
were transferred to   transwells. Lipofectamine 2000 (5 µL) 
(Invitrogen, Karlsruhe,   Germany) was added to each well 
at time points of 48, 24, and 12 hours for each group, and 
the medium in each well was replaced with DMEM with 
10% fetal bovine serum 6 hours later. Eighteen hours 
later, cells were harvested for Western blot and reverse 
transcription-polymerase chain reaction   (RT-PCR). For 
immunofluorescence analysis, cells which were grown 
on cover lips in transwells were subjected to the same 
  treatments as Western blot and RT-PCR. Cells treated by 
DMEM with 10% fetal bovine serum and transfected with 
100 nm siRNA for 24 hours were used for blank control 
and positive control, respectively.
rT-PCr
Total RNA was extracted using Trizol reagent (Life Tech-
nologies, Gaithersburg, MD). The integrity of the RNA was 
checked by 2% agarose gel electrophoresis. Approximately 
2 µg RNA was reverse-transcribed following the protocol 
of the Super Script™ first-strand synthesis system. CDNAs 
encoding PKCα and GAPDH genes were amplified by PCR 
as follows: denaturation at 94°C for 30 seconds, annealing at 
63°C for 30 seconds and elongation at 72°C for 45 seconds. 
Primer sequence was designed using Primer 3. For PKCα, 
the forward primer was 5′-ATCCGCAGTGGAATGAGTC
CTTTACAT-3′, and the reverse primer was 5′-TTGGAAG
GTTGTTTCCTGTCTTCAGAG-3′. A housekeeping gene, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
was used as the internal control. The forward primer was 
5′-ACCCAGAAGACTGTGGATGG-3′, and the reverse 
primer was 5′-TGCTGTAGCCAAATTCGTTG-3′. PCR 
products were analyzed by agarose (2%) gel electrophoresis. 
Quantifications of signal intensity were confirmed using a International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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specific computer program (Image J 1.43U software, Wayne 
Rasband, National Institutes of Health, USA).
Preparation of cell extracts
The medium was removed and the plates were washed twice 
with ice-cold phosphate buffered saline (PBS). The human 
RPE cells were lysed with sample buffer that contained 
60 mM Tris, pH 6.8, 2% (w/v) sodium dodecyl sulfate (SDS), 
100 mM 2-mercaptoethanol, and 0.01% (w/v) bromophenol 
blue.27 The lysate was then incubated on ice for 30 minutes. 
The lysate was scraped using a cell scraper and harvested 
using a pipettor, then centrifuged at 4°C for 30 minutes. 
The supernatant was collected and boiled for 5 minutes and 
stored at −20°C.
Western blot analysis
Cellular extracts from human RPE cells were processed 
for Western blot analysis.28 Briefly, 60 µg of protein per 
well was loaded on a 10% SDS-polyacrylamide gel electro-
phoresis (PAGE) gel. The protein was electro-transferred 
to polyvinylidene difluoride membranes (Millipore, 
Billerica, MA) for 1 hour at 350 mA, then blocked with 
Tris-buffered saline (TBS) containing 5% nonfat milk and 
0.1% Tween-20 (TBST) for 1 hour and incubated with 
mouse anti-PKCα (BD Systems, Torrance, CA) overnight. 
After three washes with TBST, the membranes were incu-
bated with   horseradish peroxidase conjugated secondary 
antibody for 1 hour at room temperature and washed 
with TBST. Localization of the antibody was detected by 
chemiluminescence using the ECL kit (Cell Signaling, 
Danvers, MA) following the manufacturer’s instructions. 
β-actin (Boster Biologic Technology Ltd, Wuhan, China) 
was used as an internal control.
Immunofluorescence analysis
After treatment, cells were fixed for 15 minutes in 4% 
paraformaldehyde, and then rinsed three times in PBS. All 
reagent incubations were performed in a humidified chamber. 
The mouse anti-PKCα was incubated for 16 hours in PBS 
at room temperature; horse serum was used as the negative 
control instead of the primary antibody. After washing four 
times for 10 minutes in PBS, fluorescein isothiocyanate-
labeled secondary antibodies were incubated for 40 minutes 
at 37°C. Then Hoechst 33342 was incubated for 10 minutes 
at room   temperature. After three rinses in PBS, cover slips 
were mounted onto glass slides and analyzed on a Zeiss 
laser scanning confocal microscope (LSCM 510 META; 
Oberkochen, Germany).
statistical analysis
All data were expressed as mean ± standard deviation 
(SD). All experiments were repeated at least 4 times, and 
similar results were obtained. One-way analysis of vari-
ance (ANOVA), the test of homogeneity of variances, and 
a post hoc test (Bonferroni test) were used to determine 
significant differences between the treated groups and 
the control groups. P , 0.05 was considered statistically 
significant.
Results
selectivity and acceptability  
of the standard curve
A representative result of the standard curve is shown in 
Figure 2A. The standard curve showed a very good linear 
relationship (y = 2976.3x, R2 = 1), demonstrating that the 
method selected had good selectivity and acceptability.
In vitro release of sirNA-PKCα
The cumulative release of siRNA-PKCα from FCVB is 
shown in Figure 2B–2G. SiRNA-PKCα released from 
the capsules of FCVB increased with time in a 96-hour 
experimental time period. The content (y) had a good linear 
relationship with time (x), especially in the 600 nm group, 
indicating that the FCVB released siRNA-PKCα stably with 
time (y = 16.214x, R2 = 0.9809) (P , 0.05).
The contents released from FCVB increased accordingly, 
with siRNA-PKCα concentration rising in the FCVB. The 
released content was much greater in the 600 nm group at the 
same release time than in the other groups. All data indicated 
that siRNA-PKCα was released from the capsules of FCVB 
in a dose-dependent manner in vitro in 5 concentrations 
  during a 96-hour experiment time period.
scanning electron microscopy image  
of the FCVB
Before the experiment, scattered mini apertures of 300 nm 
could be seen in the capsule of FCVB by scanning electron 
microscopy. Figure 3A shows 2 of the typical apertures. After 
a 96-hour experimental time period, 300-nm mini apertures 
still existed in the capsules, as shown in Figure 3B. No great 
changes were observed in the capsule apertures by scanning 
electron microscopy.
PKCα downregulation after treatment  
by sirNA-PKCα released from FCVB
As shown in Figure 4A1 and 4A2, RT-PCR results showed 
that PKCα messenger RNA (mRNA) was significantly International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Figure  3  scanning  electron  microscope  images  of  the  capsule  of  the  foldable 
capsular vitreous body. Mini apertures of 300 nm in the capsules were observed 
before the release (A) and at the end of the experiment time (B) (arrows).
Figure 2 Standard curve and in vitro release profile in the cumulative amount of five different concentrations. (A) The standard curve had a very good linear relationship. 
With the absorbance (x) increase, the small interfering rNA–protein kinase Cα (sirNA-PKCα) concentration (y) rose accordingly (y = 2976.3x, R2 = 1). B–G) Time 
and dose-dependent release. The sirNA-PKCα released from the foldable capsular vitreous body (FCVB) increased in a linear manner with time. Of the five different 
concentrations, the 600 nM group had a best linear relationship (y = 16.214x, R2 = 0.9809). When sirNA-PKCα concentration rose inside the FCVBs, the content released 
from the capsules rose accordingly. The tendency began from 1 hour, and lasted until 96 hours. 
Notes: results shown were representative of four repeated experiments. The concentrations of different time points are statistically different (P , 0.05). The data are 
expressed as the mean ± standard deviation (sD).
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downregulated following 24-hour release siRNA-PKCα 
treatments in the 400 nm, 500 nm, and 600 nm release 
groups. Consistent with a change at the mRNA level, the 
PKCα protein after treatment decreased 45.1% ± 6.73%, 
50.8% ± 4.96%, and 54.3% ± 3.62% in the 400 nm, 500 nm, 
and 600 nm release groups, respectively, and 64.0% ± 4.5% 
in the positive control of 100 nm siRNA-PKCα treated 
group compared with that in the untreated control group 
(Figure 4B1 and 4B2). In the untreated RPE cells, both the 
mRNA and protein level remained constant. These data 
indicate that siRNA-PKCα can actually be released from 
the FCVBs and further decrease expression of PKCα in 
cultured human RPE cells.
We further examined the expression changes of PKCα 
using immunocytochemistry. The cultured human RPE 
cells formed a monolayer with typical polygonal cellular 
arrays, as shown in Figure 5. Compatible with findings 
from RT-PCR and Western blot analysis, staining of PKCα 
decreased significantly after exposure to both 100 nm 
siRNA-PKCα and siRNA-PKCα released from FCVBs. 
Compared with the positive control of 100 nm siRNA-
PKCα treated group, the stain did not change greatly in 
the experimental groups.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Discussion
In this study, we determined the siRNA-PKCα release of a 
nonbiodegradable device (FCVB) and its effect on PKCα 
in cultured human RPE cells. Our present study indicates 
that FCVB can mechanically and sustainably release 
  siRNA-PKCα in a time-dependent and dose-dependent 
manner during a 96-hour experimental time period. 
  Furthermore, PKCα was decreased in RPE cells treated with 
siRNA-PKCα released from FCVBs. However, compared 
with the positive control group, expression of the target 
protein did not decrease remarkably with our experimen-
tal systems even in the presence of transfection reagents.   
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Figure 4 expression of protein kinase Cα (PKCα) messenger rNA (mrNA) and protein downregulation by released small interfering rNA (sirNA)-PKCα in retinal 
pigment epithelium (rPe) cells. A1, A2) rT-PCr showed that released sirNA-PKCα reduced the mrNA levels of PKCα significantly compared with control groups. 
*P , 0.05 vs the corresponding value for control groups. Data are the mean ± standard deviation of quadruplicates from an experiment that was repeated with similar results 
(sirNA100 means rPe cells treated with 100 nM sirNA-PKCα; r400, r500, and r600 mean rPe cells treated with sirNA-PKCα released from foldable capsular vitreous 
bodies containing 400, 500, and 600 nM sirNA-PKCα). B1, B2) Western blot showed that released sirNA-PKCα reduced the protein levels of PKCα significantly compared 
with control groups.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 5 Confocal images of protein kinase Cα (PKCα) expression in retinal pigment epithelium (rPe) cells by different treatments. PKCα staining was much lighter in the 
small interfering rNA (sirNA)-PKCα treatment than in the control, with no significant difference in the released siRNA-PKCα treatment groups. (A) blank control. (B) rPe 
cells treated with 100 nM sirNA-PKCα. (C–E) rPe cells treated with sirNA-PKCα released from foldable capsular vitreous bodies containing 400, 500, and 600 nM sirNA-
PKCα, respectively. (1) PKCα staining in the cytoplasm and nuclei of rPe cells. (2) staining of the nuclei with hoechst 33342. (3) An overlay of images 1 and 2. scale bars, 
20 µm. Magnification × 1000.
This is likely attributable to the fact that our FCVB drug 
delivery system released siRNA-PKCα progressively and 
to the fact that siRNA-PKCα of the positive control group 
reached peak concentration quickly. The present results were 
consistent with a previous study that FCVB can sustainably, 
mechanically release DexP via the apertures of the capsule 
in a time-dependent and dose-dependent manner.18
In this study, siRNA-PKCα was shown to be fairly 
permeable through the capsule apertures of FCVB and to 
downregulate PKCα in RPE cells. We speculated that there 
were two main factors involved in the mechanism. The first 
is the concentration gradient of siRNA-PKCα. With the 
concentration gradient increase, siRNA-PKCα released 
from the FCVBs subsequently increased, as shown in International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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  Figure 2B-2G. Second, the diffusion coefficient was related 
to the concentration gradient. The two factors mentioned 
previously have been reported by Acharya and colleagues in 
a homogeneous poly(lactic-co-glycolic acid) microstructures 
drug release system.29
The current intraocular DDS confronts some major 
disadvantages. For example, they are opaque, may interfere 
with vision, and result in a nonuniform drug distribution.30 
In contrast to the current intraocular DDS, FCVB has good 
transparency and induces very little refractive shift,31 per-
mitting the siRNA-PKCα in solution to make direct contact 
with the retina and achieve targeted drug delivery. Therefore, 
the FCVB can sustainably and mechanically release drugs 
without changing their chemical properties, and may provide 
a common vehicle for releasing different drugs.
The ideal intravitreal DDS is a kind of material that is not 
only an intravitreal drug delivery system but also a vitreous 
tamponade agent.30 Previous studies demonstrated that FCVB 
was a fine vitreous substitute that closely mimicked vitreous 
morphology and restored its physiological functions, such as 
support and cellular barriers, during a 3-month implantation 
period without the obvious complications commonly induced 
by silicone oil.32 In our study, siRNA-PKCα was released 
from FCVB in a time-dependent and a dose-dependent 
manner in vitro. SiRNA-PKCα was detected until 96 hours, 
indicating that FCVB can be used as a DDS in addition to 
serving as a vitreous substitute.
Instability is one of the essential obstacles of the RNAi 
therapeutic applications.33 SiRNA is easily degraded by 
nucleases in vitro and in vivo. Andrieu-Soler and his col-
leagues have demonstrated that there was high nuclease 
activity in the vitreous.34 To solve the problem, siRNA-PKCα 
combined with FCVB shows great advantages. On the one 
hand, chemically synthesized siRNA-PKCα was mixed with 
the suspension of 2 deoxyribose nucleotides to increase the 
stability in its 3′ end; on the other hand, siRNA-PKCα was 
injected into the capsule of FCVB, protecting it from contact-
ing nucleases in vitro and in vivo. In addition, Ambati J and 
colleagues reported that 21-nt or longer siRNAs suppress 
hemanogiogenesis and lymphangiogenesis in various mouse 
models of neovascularization in a sequence- and target-
independent manner through activating cell surface Toll-like 
receptor 3.35,36 Therefore, it is critical to address the safety 
issue using in vivo systems.
The underlying factor in many vision-threatening vitreo-
retinal diseases is unwanted intraocular cell proliferation.37 
In the pathology of PVR, proliferating RPE cells are thought 
to be an initiating factor.5–8 In a previous study, we found 
that PKCα affects the cell cycle progression and prolifera-
tion in RPE cells through the downregulation of p27kip1.14 
Since PKCα was downregulated after exposure to siRNA-
PKCα released from FCVB, it may be a rational approach 
for targeted therapies against RPE cell proliferation and 
PVR disease.
Intravitreal sustained-release systems are exciting new 
modalities of drug delivery that offer effective treatment of 
some visually devastating diseases.38 SiRNA-PKCα combined 
with FCVB shows great prospects for preventing PVR, and 
it will greatly reduce the suffering and economic burden of 
patients. As a public release vehicle, FCVB has the potential 
to release several drugs at the same time, which will meet the 
requirements of drug combinations for many diseases.
In conclusion, FCVB can sustainably and mechanically 
release siRNA-PKCα via capsule apertures in a time-
  dependent and dose-dependent manner in addition to serving 
as a vitreous substitute. The in vitro study demonstrated that 
PKCα was inhibited after exposure to siRNA-PKCα released 
from FCVBs. The present research offers a new avenue for 
the treatment of diseases of the posterior segment of eyes, 
especially proliferative eye diseases.
Conclusion
In this study, we developed a FCVB drug delivery system 
to release siRNA-PKCα to inhibit PKCα expression in 
RPE cells in vitro. We found that PKCα was significantly 
  downregulated by siRNA-PKCα released from FCVB, pro-
viding a new avenue to prevent PVR.
Acknowledgments
This study was supported by Natural National Science 
Foundation of China (NSFC-30973258) and the National 
Basic Research Program of China (“973” program, Number 
2007CB512200). The Eye Bank of Zhongshan Ophthalmic 
Center is thanked for providing eye cups for primary cell 
culture.
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Sunalp MA, Wiedemann P, Sorgente N, Ryan SJ. Effect of adriamycin 
on experimental proliferative vitreoretinopathy in the rabbit. Exp Eye 
Res. 1985;41(1):105–115.
2.  Cowley M, Conway BP, Campochiaro PA, Kaiser D, Gaskin H. Clinical 
risk factors for proliferative vitreoretinopathy. Arch Ophthalmol. 1989; 
107(8):1147–1151.
3.  Kirchhof B. Strategies to influence PVR development. Graefes Arch Clin 
Exp Ophthalmol. 2004;242(8):699–703.International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1311
PKCα downregulation via sirNA-PKCα
  4.  Cardillo JA, Stout JT, LaBree L, et al. Post-traumatic proliferative 
vitreoretinopathy. The epidemiologic profile, onset, risk factors, and 
visual outcome. Ophthalmology. 1997;104(7):1166–1173.
  5.  Murphy TL, Sakamoto T, Hinton DR, et al. Migration of retinal pigment 
epithelium cells in vitro is regulated by protein kinase C. Exp Eye 
Res. 1995;60(6):683–695.
  6.  Harris MS, Sakamoto T, Kimura H, et al. Hypericin inhibits cell growth 
and induces apoptosis in retinal pigment epithelial cells: possible 
involvement of protein kinase C. Curr Eye Res. 1996;15(3):255–262.
  7.  Sheu SJ, Sakamoto T, Osusky R, et al. Transforming growth factor-
beta regulates human retinal pigment epithelial cell phagocytosis by 
influencing a protein kinase C-dependent pathway. Graefes Arch Clin 
Exp Ophthalmol. 1994;232(11):695–701.
  8.  Sakamoto T, Hinton DR, Sakamoto H, et al. Collagen gel contraction 
induced by retinal pigment epithelial cells and choroidal fibroblasts 
involves the protein kinase C pathway. Curr Eye Res. 1994; 
13(6):451–459.
  9.  Nishizuka  Y. The molecular heterogeneity of protein kinase C and its impli-
cations for cellular regulation. Nature. 1988;334(6184):661–665.
  10.  Moriarty P, Dickson AJ, Erichsen JT, Boulton M. Protein kinase C 
isoenzyme expression in retinal cells. Ophthalmic Res. 2000;32(2–3): 
57–60.
  11.  Evans VG. Multiple pathways to apoptosis. Cell Biol Int. 1993;17(5): 
461–476.
  12.  Kizaki H, Suzuki K, Tadakuma T, Ishimura Y. Adenosine receptor-
mediated accumulation of cyclic AMP-induced T-lymphocyte 
death through internucleosomal DNA cleavage. J Biol Chem. 1990; 
265(9):5280–5284.
  13.  Yu K, Ma P, Ge J, et al. Expression of protein kinase C isoforms in 
cultured human retinal pigment epithelial cells. Graefes Arch Clin Exp 
Ophthalmol. 2007;245(7):993–999.
  14.  Gao Q, Tan J, Ma P, et al. PKC alpha affects cell cycle progression 
and proliferation in human RPE cells through the downregulation of 
p27kip1. Mol Vis. 2009;15:2683–2695.
  15.  Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. Topical and sys-
temic drug delivery to the posterior segments. Adv Drug Deliv Rev. 
2005;57(14):2010–2032.
  16.  Cunha-Vaz JG. The blood-ocular barriers: past, present, and future. Doc 
Ophthalmol. 1997;93(1–2):149–157.
  17.  Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y. Drug 
delivery systems for vitreoretinal diseases. Prog Retin Eye Res. 2004; 
23(3):253–281.
  18.  Liu Y, Ke Q, Chen J, et al. Sustained mechanical release of dexametha-
sone sodium phosphate from a foldable capsular vitreous body. Invest 
Ophthalmol Vis Sci. 2010;51(3):1636–1642.
  19.  Liu Y, Jiang Z, Gao Q, et al. Technical standards of a foldable capsu-
lar vitreous body in terms of mechanical, optical, and biocompatible 
properties. Artif Organs. 2010;34(10):836–845.
  20.  Lin X, Ge J, Gao Q, et al. Evaluation of the flexibility, efficacy, and 
safety of a foldable capsular vitreous body in the treatment of severe 
retinal detachment. Invest Ophthalmol Vis Sci. 2011;52(1):374–381.
  21.  Gao Q, Mou S, Ge J, et al. A new strategy to replace the natural vitreous 
by a novel capsular artificial vitreous body with pressure-control valve. 
Eye (Lond). 2008;22(3):461–468.
  22.  Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a 
bidentate ribonuclease in the initiation step of RNA interference. 
Nature. 2001;409(6818):363–366.
  23.  Novina CD, Sharp PA. The RNAi revolution. Nature. 2004;430(6996): 
161–164.
  24.  Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) 
targeting VEGF effectively inhibits ocular neovascularization in a 
mouse model. Mol Vis. 2003;9:210–216.
  25.  Nakamura H, Siddiqui SS, Shen X, et al. RNA interference targeting 
transforming growth factor-beta type II receptor suppresses ocular 
inflammation and fibrosis. Mol Vis. 2004;10:703–711.
  26.  Cinatl J Jr, Michaelis M, Fleckenstein C, et al. West Nile virus infection 
induces interferon signaling in human retinal pigment epithelial cells. 
Invest Ophthalmol Vis Sci. 2006;47(2):645–651.
  27.  Campa MJ, Wang MZ, Howard B, Fitzgerald MC, Patz EF Jr. Protein 
expression profiling identifies macrophage migration inhibitory factor 
and cyclophilin a as potential molecular targets in non-small cell lung 
cancer. Cancer Res. 2003;63(7):1652–1656.
  28.  Weaver SA, Schaefer AL, Dixon WT. Western blotting for detection of 
glucocorticoid receptors in the brain and pituitary gland from adrenal 
intact pigs. Brain Res. 2000;869(1–2):130–136.
  29.  Acharya G, Shin CS, Vedantham K, et al. A study of drug release 
from homogeneous PLGA microstructures. J Control Release. 2010; 
146(2):201–206.
  30.  Colthurst MJ, Williams RL, Hiscott PS, Grierson I. Biomaterials used in 
the posterior segment of the eye. Biomaterials. 2000;21(7):649–665.
  31.  Gao Q, Chen X, Ge J, et al. Refractive shifts in four selected artificial 
vitreous substitutes based on Gullstrand-Emsley and Liou-Brennan 
schematic eyes. Invest Ophthalmol Vis Sci. 2009;50(7):3529–3534.
  32.  Chen J, Gao Q, Liu Y, et al. Clinical device-related article evaluation of 
morphology and functions of a foldable capsular vitreous body in the rab-
bit eye. J Biomed Mater Res B Appl Biomater. 2011;97(2):396–404.
  33.  Fattal E, Barratt G. Nanotechnologies and controlled release systems for 
the delivery of antisense oligonucleotides and small interfering RNA. 
Br J Pharmacol. 2009;157(2):179–194.
 34.  Andrieu-Soler C, Bejjani RA, de Bizemont T, Normand N, BenEzra D,   
Behar-Cohen F. Ocular gene therapy: a review of nonviral strategies. Mol 
Vis. 2006;12:1334–1347.
  35.  Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-
independent angiogenesis suppression by siRNA via TLR3. Nature. 
2008;452(7187):591–597.
  36.  Cho WG, Albuquerque RJ, Kleinman ME, et al. Small interfering 
RNA-induced TLR3 activation inhibits blood and lymphatic vessel 
growth. Proc Natl Acad Sci U S A. 2009;106(17):7137–7142.
  37.  Cheng L, Hostetler K, Valiaeva N, et al. Intravitreal crystalline drug 
delivery for intraocular proliferation diseases. Invest Ophthalmol Vis 
Sci. 2010;51(1):474–481.
  38.  Guidetti B, Azéma J, Malet-Martino M, Martino R. Delivery systems 
for the treatment of proliferative vitreoretinopathy: materials, devices 
and colloidal carriers. Curr Drug Deliv. 2008;5(1):7–19.